



ASX/MEDIA RELEASE

10th Patient treated with PAD implant – ground breaking global treatment

31 January 2008: Leading Australian developer and manufacturer of prosthetic implants and medical devices, Advanced Surgical Design and Manufacture Limited (ASDM) (ASX: AMT) is pleased to announce that the tenth Peripheral Access Device (PAD) was implanted in a patient in Sydney yesterday.

This program is part of the ongoing clinical trial in vascular surgery treating patients with gangrene as a result of peripheral arterial disease. This is a late stage treatment where there is no other alternative but limb amputation. It is a groundbreaking treatment with a substantial global need and the clinical program is seeking to prove its efficacy against this background.

Results from patient treatment are being collated and will be released in due course. The clinical trial currently underway is expected to be completed by the end of calendar 2008. In the meantime, the company is preparing a submission for the TGA regarding the requirements of the clinical program and criteria for final assessment.

ASDM CEO, Dr Greg Roger said,

“We are pleased with the progress of this exciting trial, designed to establish the effectiveness of the treatment and to secure Regulatory approval and CE Marking.”

“The device has been proven safe and efficacious up to 30 days in animal trials. Should the human trials meet expectations, ASDM will have an enormous opportunity in addressing a potentially very large market where there are no other options.”

Contact Details: Company

Dr Greg Roger
Managing Director
Advanced Surgical Design
& Manufacture Limited
T: 61 2 9439 4448

Investor Relations

Rod North
Executive Director
Bourse Communications Pty Ltd
T: 61 3 9510 8309
M: 0408 670 706

For personal use only

ABOUT THE PERIPHERAL ACCESS DEVICE

ASDM has the exclusive worldwide manufacturing rights to the Peripheral Access Device (PAD), which aims to improve the lives of patients suffering vascular insufficiency, or Peripheral Vascular Disease (PVD). In the western world alone, more than 300,000 legs are amputated each year due to PVD, primarily caused by smoking and diabetes.

The PAD, which was designed and engineered by ASDM enables the delivery of a unique treatment, developed by a leading vascular surgeon, in affected patients. ASDM worked with the surgeon in developing the device through bench testing, animal testing and now human trials.

This treatment is novel and meets a need, particularly for those with the advanced stage of the disease. The key to this device is the ability to access the patient's arteries at large diameter, intermittently, with the device remaining implanted until after the course of treatments is complete. Between treatment sessions the device is sealed and it is envisaged that the patient will be able to stay at home.

ABOUT ASDM

ASDM designs and manufactures medical devices. Its principal product is the Active Knee, a prosthetic implant of which more than 3,000 have been implanted including 600+ in 2007. This product is supported by a range of Orthopaedic accessories and surgical tools and other Orthopaedic products.

ASDM provides a highly effective integrated service to surgeons building on its strengths in design and engineering. Core capabilities that underpin this service are integrated design and engineering, regulatory/compliance competency, manufacturing, distribution and customer service.

The company has built an extensive patent and product development portfolio through collaborative research relationships with universities, companies and surgeon inventors that extends beyond orthopaedics. These collaborations are yielding promising projects in several specialities with strong prospects for commercialisation over the next few years.

For more information, please visit www.asdm.com.au